Navigation Links
WuXi PharmaTech Announces Second Quarter 2007 Results
Date:9/5/2007

- Net Revenues Up 99% Year-Over-Year

SHANGHAI, China, Sept. 5 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or "the Company"), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the second quarter ended June 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Second Quarter 2007 Highlights:

-- Total net revenues increased 99.3% over the second quarter of 2006 to

US$30.2 million.

-- Net income increased 482.1% over the second quarter of 2006 to US$7.1

million.

-- Diluted earnings per American Depositary Share ("ADS") for the second

quarter of 2007 was US$0.11. Diluted earnings per ADS excluding share-

based compensation expenses (non-GAAP) for the second quarter of 2007

was US$0.13.

"During the second quarter of 2007, we experienced strong revenue and earnings growth compared to the same period last year," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "We achieved solid growth throughout our business divisions, with revenue from laboratory services up 102.1% and revenue from research manufacturing up 86.8%. In the second quarter of 2007, laboratory services remained the major revenue contributor, accounting for 83.1% of our total net revenues, with research manufacturing accounting for the remainder. Our strong revenue growth was driven by the robust demand for drug R&D outsourcing services that we provide, and was a direct result of our ability
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NJ (PRWEB) May 21, 2015 Patent ... a method for diagnostic or therapeutic imaging within a ... apparatus uses an endoscope having a low cost, single-use ... USPTO filing date was October 18, 2013 and the ... The technology enables the physician to customize the lighting ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
(Date:5/20/2015)... global genotyping market is expected to grow at a ... to 2020 to reach $17.0billion in 2020. Genotyping tests ... process and to provide personalized therapy, factors that are ... key manufacturers to offer advanced and innovative products for ... market data tables & 37 figures spread through 200 ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... DARA BioSciences(TM),(Nasdaq: DARA ) announced today the appointment ... Mr. Cochrane was appointed to fill a Board,vacancy and ... appointment was effective February 21, 2008., In making ... are pleased that Haywood has joined us as a ...
... PITTSBURGH, Feb. 27 Mylan Inc. (NYSE: ... Holdings, Ltd., a wholly,owned subsidiary of Forest Laboratories, ... 2006 agreement to commercialize, develop and distribute the,novel ... in,the United States for the treatment of hypertension. ...
... ZARS Pharma, Inc. announced,today that Rapydan(R) (70 ... received marketing authorization in Sweden, the United ... Republic, Greece, Ireland,Norway and Portugal following the ... Pharma has licensed the European sales and,marketing ...
Cached Biology Technology:DARA BioSciences, Inc. Announces Appointment of New Director to Board 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 3ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 2ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 3
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... University has completed the first comprehensive map of the ... of higher organisms operate, according to a report this ... is a breakthrough in understanding mechanisms of how proteins ... master regulator molecules called protein kinases. Although protein kinases ...
... volcanic rock in Mexico are either extremely old - more ... presence in the Western Hemisphere - or not footprints at ... Nature. , The study was conducted by geologists at the ... part of an investigative team of geologists and anthropologists from ...
... strand of molecules plays a role in how our arms ... light on perplexing bits of material once dismissed as genetic ... University. , The research, available today in the online edition ... called microRNAs act as protective mechanisms in healthy development not ...
Cached Biology News:Yale scientists decipher 'wiring pattern' of cell signaling networks 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 3Alleged 40,000-year-old human footprints in Mexico much, much older than thought 4MicroRNA may have fail-safe role in limb development 2